Fierce Biotech April 16, 2024
After setting up more than $30 billion in medtech M&A spending within less than two years, Johnson & Johnson CEO Joaquin Duato said that trajectory will continue as the company looks to latch on to long-term growth.
In cardiovascular therapies alone, J&J’s recently proposed $13.1 billion buyout of artery opener Shockwave Medical serves as the sequel to its $16.6 billion deal for heart pump maker Abiomed, inked in late 2022. In between, the company also threw in $400 million late last year for cardiac implant developer Laminar for good measure.
Together, the weight of those outlays could be seen in J&J’s first-quarter earnings report, where the division previously referred to as “Interventional Solutions” has been simply renamed “Cardiovascular.” Meanwhile, on...
Today's Sponsors
Today's Sponsor